LIEN NGUYEN: Open Payments
NPI 1508906033 · MISSION VIEJO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$7,245 in 96 payments from 17 companies in 2025. Trend: 2023 $2,444 · 2024 $2,054 · 2025 $7,245
Speaker / faculty: $4,050Food & beverage: $3,195
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 12 | $4,381 |
| Aimmune Therapeutics, Inc. | 20 | $795 |
| Madrigal Pharmaceuticals | 7 | $567 |
| ABBVIE INC. | 9 | $276 |
| GENZYME CORPORATION | 8 | $258 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $207 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $162 |
| Medtronic, Inc. | 1 | $143 |
| Lilly USA, LLC | 4 | $100 |
| VIVUS LLC | 4 | $92 |
Products named: TREMFYA, ZENPEP, REZDIFFRA, DUPIXENT, XIFAXAN, CREON, BARRX, ENTYVIO.
Industry payments across CA — which companies pay providers there.
